title: Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
abstract: Pancreatic adenocarcinoma is the fourth cause of cancer-related death in the United States. Surgery is the only potentially curative treatment, but most patients present at diagnosis with unresectable or metastatic disease. Moreover, even with an R0 resection, the majority of patients will die of disease recurrence. Most recurrences occur in the first 2-year after pancreatic resection, and are commonly located in the abdomen, even if distant metastases can occur. Recurrent pancreatic adenocarcinoma remains a significant therapeutic challenge, due to the limited role of surgery and radio-chemotherapy. Surgical management of recurrence is usually unreliable because tumor relapse typically presents as a technically unresectable, or as multifocal disease with an aggressive growth. Therefore, treatment of patients with recurrent pancreatic adenocarcinoma has historically been limited to palliative chemotherapy or supportive care. Only few data are available in the Literature about this issue, even if in recent years more studies have been published to determine whether treatment after recurrence have any effect on patients outcome. Recent therapeutic advances have demonstrated the potential to improve survival in selected patients who had undergone resection for pancreatic cancer. Multimodality management of recurrent pancreatic carcinoma may lead to better survival and quality of life in a small but significant percentage of patients; however, more and larger studies are needed to clarify the role of the different therapeutic options and the optimal way to combine them.
authors.affiliation: Cosimo Sperti, Lucia Moletta, Stefano Merigliano, Department of Surgery, Oncology and Gastroenterology, 3 Surgical Clinic, University of Padua, 35128 Padua, Italy.
authors.forename: Cosimo
authors.initials: C
authors.lastname: Sperti
authors.affiliation: Cosimo Sperti, Lucia Moletta, Stefano Merigliano, Department of Surgery, Oncology and Gastroenterology, 3 Surgical Clinic, University of Padua, 35128 Padua, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Moletta
authors.affiliation: Cosimo Sperti, Lucia Moletta, Stefano Merigliano, Department of Surgery, Oncology and Gastroenterology, 3 Surgical Clinic, University of Padua, 35128 Padua, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Merigliano
keywords: Multimodality treatment; Pancreas; Pancreatectomy; Pancreatic neoplasms; Tumor’s recurrence